Long-term open-trial of mizoribine with prednisolone in 24 patients with multiple sclerosis: Safety, clinical and magnetic resonance imaging outcome

Internal Medicine

Volumn 38, Issue 8, 1999, Pages 636-642

  Saida, Kyoko ^b   Zhigang, Zhao ^a   Ozawa, Kyoko ^a   Konishi, Tetsuro ^a   Saida, Takahiko ^a  

^a UTANO NATIONAL HOSPITAL   (Japan)

^b Nishinara National Hospital   (Japan)

Author keywords

Immunosuppressant; Japanese; Magnetic resonance imaging (MRI); Treatment

Indexed keywords

MIZORIBINE; PREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DISABILITY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PURINE SYNTHESIS; RELAPSE; REMISSION; TREATMENT OUTCOME;

EID: 0032804203     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.38.636     Document Type: Article

References (20)

1. Matthews WB, Matthews WB (ed) McAlpine's Multiple Sclerosis. Churchill Livingstone, Edinburgh London Melborne New york, p251-267, 1991.
2. Mizuno K, Tsujino M, Takada M, et al. Studies on bredinin. I. Isolation, characterization and biological properties. J Antibiot (Tokyo) 27: 775-782, 1974.
3. Yoshizawa M, Tujino M, Mizuno K, Hayano K. Basic studies on immunosuppression of mizoribine (bredinin). II. Supression of humoral and cellular immune responses.Rinsho Menèki(Clinical Immunology) 14: 561-570, 1982 (in Japanese).
4. Hosoda Y, Kato S, Ohhama E. Suppression of relapsing experimental allergic encephalomyelitis by mizoribine: clinical, histological and immunohistochemical studies. Neuropathology 16: 15-20, 1996.
5. Mizobuchi M, Sako K, Iwasaki Y, Ohara Y, Terunuma H, Tsunoda I. Suppression of acute active experimental allergic encephalomyelitis with mizoribine is correlated with selective reduction of CD4+CD45RC-cells in the peripheral blood in Lewis rats. Brain Pathology 4:497, 1994 (Abstract).
6. Honma M, Akizuki M, Yokohari R, Hashimoto H, Kashiwazaki S, Kondo H, Irimajiri S. Clinical evaluation of mizoribine on lupus nephritis. Multicenter single-blind comparative study with inactive placebo. Rinsho Iyaku (Clinical Drugs) 5: 795-824, 1989 (Abstract in English).
7. Shiokawa Y, Hirose T, Warabi H, et al. Clinical evaluation of mizoribine(Bredinin) on rheumatoid arthritis. Nippon Enshougakkai Zasshi (Japanese Journal of Inflammation) 8: 263-275, 1988 (in Japanese).
8. Inao T. Immunosupressive effects of Bredinin on renal transplantation: summarized by Bredinin Research Committee. Ishoku (Transplantation) [suppl] 17: 547-561, 1982 (Abstract in English).
9. Saida T, Ohhashi Y, Tashiro K, et al. Treatment of multiple sclerosis with mizoribine. Randomized controlled double-blind study (1) clinical results. Neuroimmunology (shinnkei menèkigaku) 6: 160-161, 1998 (in Japanese).
10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol 13: 227-231, 1983.
11. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33: 1444-1452, 1983.
12. Shibasaki H, Kubo N, Nishitani H, et al. Nationwide survey of multiple sclerosis in Japan: reappraisal of clinical features. J Tropical Geographical Neurology 2: 73-82, 1992.
13. Milligan NM, Newcombe R, Compson DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. clinical effects. J Neurol Neurosurg Psychiatry 50: 511-516, 1987.
14. Ellison GW, Myers LW, Mickey MR, et al. A placebo-controlled, randmized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 39: 1018-1026, 1989.
15. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet ii (No. 8604, July 23): 179-183, 1988.
16. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43: 910-918, 1993.
17. Rudge P, Koetsier JC, Mertin J, et al. Randomized double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry 52: 559-565, 1989.
18. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344: 9-13, 1994.
19. Edan G, Millar D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randmised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiat 62: 112-118, 1997.
20. Goodkin DE, Rudick RA, VanderBrug Medenrorp S, Daughtry MM, Van Dyke C. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology 47: 1153-1157, 1996.